Clinical Trial Update: Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the potential interaction between Verapamil Immediate Release and SAM-531 when co-administered in Alzheimer disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-531
• Verapamil Immediate Release (verapamil)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED